AIC
ALNY icon

Ameritas Investment Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ameritas Investment Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-18
Closed -$2.54K – 772
2021
Q1 		$2.54K Buy
+18
New +$2.71K ﹤0.01% 1864
2019
Q2 		– Sell
-8
Closed -$1K – 250
2019
Q1 		$1K Sell
8
-141
-95% -$11.8K ﹤0.01% 878
2018
Q4 		$11K Buy
+149
New +$11.5K ﹤0.01% 1009

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameritas Investment Company's ALNY Position: Q2 2021 in Review

Ameritas Investment Company sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2021, closing a stake of 18 shares — an estimated $2.54K sold.

Ameritas Investment Company first reported a position in ALNY in Q4 2018 and held it in 3 quarters. The position peaked at $11K in Q4 2018. 401 funds tracked by Wall St. Rank hold ALNY as of Q2 2021.

  • Ameritas Investment Company reported no remaining Alnylam Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Company sold 18 Alnylam Pharmaceuticals shares in Q2 2021, an estimated $2.54K.
  • Ameritas Investment Company first reported a position in Alnylam Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Ameritas Investment Company's Alnylam Pharmaceuticals position peaked at $11K in Q4 2018.
  • 401 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2021.

Based on Ameritas Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.